Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Multicentre, Open-label, Single-arm, Non-interventional Regulatory Post-marketing Surveillance(rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda® (Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea

NCT03560336 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT03560336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03560336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Multicentre, Open-label, Single-arm, Non-interventional Regulatory Post-marketing Surveillance(rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda® (Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Completed
Start date
July 5, 2018
Completion date
December 2, 2020
Enrollment
758 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight